These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 19565495)

  • 1. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
    Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
    Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
    Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
    Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.
    Lanternier F; Tubach F; Ravaud P; Salmon D; Dellamonica P; Bretagne S; Couret M; Bouvard B; Debandt M; Gueit I; Gendre JP; Leone J; Nicolas N; Che D; Mariette X; Lortholary O;
    Chest; 2013 Sep; 144(3):990-998. PubMed ID: 23744173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
    Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.
    Lee SK; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA
    Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
    Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
    Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
    Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
    Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers.
    Kim EM; Uhm WS; Bae SC; Yoo DH; Kim TH
    J Rheumatol; 2011 Oct; 38(10):2218-23. PubMed ID: 21844149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.
    Curtis JR; Xie F; Chen L; Muntner P; Grijalva CG; Spettell C; Fernandes J; McMahan RM; Baddley JW; Saag KG; Beukelman T; Delzell E
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1480-9. PubMed ID: 22833479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.